Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an announcement.
Eisai, in partnership with BioArctic AB, has completed the rolling submission of a Supplemental Biologics License Application to the U.S. FDA for Leqembi Iqlik, a subcutaneous autoinjector for Alzheimer’s treatment. If approved, this would allow patients to administer the treatment at home, potentially reducing healthcare resource utilization and streamlining the Alzheimer’s treatment pathway.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a biopharmaceutical company that focuses on developing innovative treatments for neurodegenerative diseases, particularly Alzheimer’s disease. The company has a strategic research alliance with Eisai, and their primary product, Leqembi, is a monoclonal antibody targeting amyloid-beta, a hallmark of Alzheimer’s.
Average Trading Volume: 316,005
Technical Sentiment Signal: Buy
Current Market Cap: SEK26.66B
For an in-depth examination of BIOA.B stock, go to TipRanks’ Overview page.